Ken Griffin Krystal Biotech, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$174.7 - $213.66 $104,820 - $128,196	-600 Reduced 7.14%	7,800 $1.42 Million
Q2 2024 Aug 14, 2024	SELL	$153.12 - $183.64 $3.94 Million - $4.72 Million	-25,700 Reduced 75.37%	8,400 $1.54 Million
Q1 2024 May 15, 2024	BUY	$108.01 - $179.35 $1.88 Million - $3.12 Million	17,400 Added 104.19%	34,100 $6.07 Million
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $96,000 - $128,289	1,000 Added 6.37%	16,700 $2.07 Million
Q3 2023 Nov 14, 2023	SELL	$108.51 - $130.22 $1.5 Million - $1.8 Million	-13,800 Reduced 46.78%	15,700 $1.82 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $910,368 - $1.51 Million	11,600 Added 64.8%	29,500 $3.46 Million
Q1 2023 May 15, 2023	SELL	$72.39 - $84.27 $579,120 - $674,160	-8,000 Reduced 30.89%	17,900 $1.43 Million
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $757,680 - $958,800	12,000 Added 86.33%	25,900 $2.05 Million
Q3 2022 Nov 14, 2022	SELL	$64.85 - $82.4 $233,459 - $296,640	-3,600 Reduced 20.57%	13,900 $969,000

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.38B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.